8/31, 8:22 AM (Source: TeleTrader)
more TeleTrader news

SK, GSK start Phase 3 COVID vaccine trial

SK bioscience (SK) and GlaxoSmithKline plc (GSK) announced on Tuesday they are starting a Phase 3 clinical trial of SK's coronavirus vaccine candidate GBP510 in combination with GSK's pandemic adjuvant.

The trial will be conducted in several countries and will include 4,000 participants. The companies noted it will be one of the first global late-stage trials to compare two different jabs as it will compare the SK jab to the one developed by Oxford University and AstraZeneca.

SK and GSK noted earlier trials showed "that all participants who received the adjuvanted vaccine candidate developed strong neutralizing antibody responses, demonstrating a 100% seroconversion rate."

Breaking the News / NP